StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

Equities research analysts at StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm cut their price objective on Aptevo Therapeutics from $20,535.00 to $10,952.00 and set a “buy” rating for the company in a research report on Monday, September 23rd.

Aptevo Therapeutics Stock Performance

Shares of Aptevo Therapeutics stock opened at $9.20 on Monday. The business has a 50-day moving average price of $297.69 and a 200-day moving average price of $489.21. Aptevo Therapeutics has a twelve month low of $5.11 and a twelve month high of $399.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is currently owned by institutional investors and hedge funds.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.